Trial Name	Description
DeLLphi-305 SCLC	Dr. D. Breadner A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
REPAIR	Dr. David Palma Not Yet Open - A Safety and Efficacy Trial of Reirradiation Dose Escalation in Thoracic Cancers: Re-evaluating previous dose and allowing increasing recovery (REPAIR)
ENDO-SABR NSCLC	Dr. Inderdeep Dhaliwal Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
PACIFIC 9 NSCLC	Dr. M. Vincent A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients with Locally Advanced (Stage III), Unresectable Non-Small Cell Lung Cancer
SKYSCRAPER 06 NSCLC	Dr. M. Vincent A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in Patients with Previo
TROPION-Lung10	Dr. M. Vincent A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants Wi
RESPIRE-ILD Lung	Dr. D. Palma Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease (RESPIRE-ILD): A 2x2 Factorial Randomized Phase II Trial testing N-Acetyl Cysteine and Dexamethasone
eVOLVE-Meso	Dr. M. Vincent A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural
SKYLITE SLC-391-102 NSCLC	Dr. Daniel Breadner A Single-Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
FORTITUDE 102 Gastric-GEJ	Dr. M. Vincent A Phase 1B/3 Study of Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone in Subjects with Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2B Overexpression
Dizal DZ2022E0005 NSCLC	Dr. J. Raphael A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Facto
OCELOT NSCLC	Dr. M. Vincent Osimertinib then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-Line Rechallenge
HARMONi-3 NSCLC	Dr. S. Kuruvilla A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
IND.242	Dr. Daniel Breadner "Not Open Yet" - Neoadjuvant Platform Trial in Patients with Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
ES.3/NEEDS GI	Dr. Michael Sanatani Not Open Yet - NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)